N(2)M(2) (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma

BACKGROUND: Patients with glioblastoma without O(6)-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with temozolomide (TMZ). Trials aiming at replacing TMZ with targeted agents in unselected patient populations have failed to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Wick, Wolfgang, Dettmer, Susan, Berberich, Anne, Kessler, Tobias, Karapanagiotou-Schenkel, Irini, Wick, Antje, Winkler, Frank, Pfaff, Elke, Brors, Benedikt, Debus, Jürgen, Unterberg, Andreas, Bendszus, Martin, Herold-Mende, Christel, Eisenmenger, Andreas, von Deimling, Andreas, Jones, David T W, Pfister, Stefan M, Sahm, Felix, Platten, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6303534/
https://ncbi.nlm.nih.gov/pubmed/30277538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy161
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados